GNLX - Genelux Corp Short-Term Debt to Capital

Symbol and logo of brand Genelux (GNLX)

The development of innovative tumor-fighting methods is being conducted within a stable US legal framework without sanction risks. The business model is based on the success of the Olvi-Vec system and the protection of immunotherapy patents, with the metric standing at 0.03. The asset's price trajectory is presented below. Genelux Corporation (GNLX) creates cutting-edge medicines by combining its scientific resources with specialized research centers to conduct joint clinical trials.

Current Liabilities to Capital: genelux.com (GNLX) for 04/28/2023 - 11/01/2026

Summary analytical data breakdowns for Genelux Corp (GNLX)

- stock value and consensus price forecast:
Price Chart Genelux Corporation|GNLX - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Genelux Corp.|GNLX - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Genelux|GNLX - Total Stockholders' Equity|Market Value to Book Value Ratio genelux.com|GNLX - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Genelux Corporation|GNLX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Genelux Corporation|GNLX - Company Total Indebtedness|Debt to Book Value Genelux Corp.|GNLX - Long-Term Debt|Company Current Liabilities Genelux|Quick Liquidity genelux.com
- company profitability and valuation multiples indicators:
GNLX - Profit After Tax
Initial company analysis:Genelux GNLX
Signature product of Genelux Corp

This ratio measures the dependence of equity on liabilities with a maturity exceeding one year. By analyzing the current trend of short-term liabilities to equity, an investor assesses the balance between financial leverage and liquidity risk. An increase in this metric signals a rising debt load, which could lead to a cash deficit. For Genelux Corporation (GNLX), this is critical when financing the costly cold chain transportation of viral vectors.

Competitors of Genelux Corporation (GNLX)

Short-Term Debt to Equity Geron Corp. (GERN)|Nanobiotix Group - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital BCYC (Bicycle Therapeutics)|CTMX - Short-Term Debt to Equity Ratio|CATX - Short-Term Debt to Equity|Current Liabilities to Capital Molecular Partners Ltd|oncolyticsbiotech.com (ONCY) - Short-Term Debt to Equity|LSTA (Lisata Therapeutics, Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Moleculin Biotech Inc|Current Liabilities to Capital Galera GRTX|Short-Term Debt to Capital MTEM